EU policy shift on gene editing likely positive for Corteva, says Jefferies

Jefferies analyst Laurence Alexander notes media reports indicating that the EU will announce a relaxation in the rules constraining the introduction and commercialization of gene edited crops, which should be a “net positive” for Corteva. The firm, which sees an expanded total addressable market and improving R&D efficiency offsetting any related EU initiatives to drive nutrient efficiency and reduce the use of crop protection chemicals, has a Buy rating and $80 price target on Corteva shares.